Company intelligence / Profile preview
Cipher Pharmaceuticals
Mississauga, Ontario, Canadacipherpharma.com ↗
- Ownership
- Public · CPH
- Employees
- ~25
- Development stage
- Commercial
01
Overview
Cipher has a diversified portfolio of commercialized dermatology products as well as late-stage clinical assets. Its lead pipeline asset MOB-015 for onychomycosis is in pivotal Phase III trials. DTR-001 for tattoo removal has completed proof-of-concept studies. The company also outlicenses several products generating royalty revenue
- Therapeutic areas
- CardiovascularImmunologyDermatologyWomen's HealthNeurologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Sun Pharmaceutical IndustriesVertical PharmaceuticalsANI PharmaceuticalsMoberg Pharma AB
04
Financials
- Market cap
- $240.5M
- Total revenue
- $51.3M
- Enterprise value
- $231.8M
Beyond the preview
Go deeper on Cipher Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cipher Pharmaceuticals.